Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis
- PMID: 33220266
- PMCID: PMC7846486
- DOI: 10.1016/j.jcmgh.2020.10.013
Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis
Comment on
-
Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System.Cell Mol Gastroenterol Hepatol. 2021;11(2):573-595. doi: 10.1016/j.jcmgh.2020.09.007. Epub 2020 Sep 19. Cell Mol Gastroenterol Hepatol. 2021. PMID: 32961356 Free PMC article.
References
-
- Ampuero J., Ranchal I., Gallego-Duran R. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. J Gastroenterol Hepatol. 2016;31:1611–1618. - PubMed
-
- Zhang Q., Liu J., Liu J. oxLDL induces injury and defenestration of human liver sinusoidal endothelial cells via LOX1. J Mol Endocrinol. 2014;53:281–293. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
